- ONY's Neonatal
U.S. Approved Drug Infasurf to Treat Respiratory Distress
Syndrome in Premature Infants In-Licensed
- Marketing and
Sales Rights Granted for Turkey, Serbia, Bosnia, Macedonia,
Albania, Egypt and Syria
 Samaritan
Pharmaceuticals Inc. (OTC BB:SPHC.OB), a developer of innovative
drugs, is pleased to announce that it has signed an exclusive
license for the marketing and sales of U.S. approved Infasurf
(calfactant), a specialist medication used to treat and
prevent respiratory distress syndrome (RDS) in premature infants.
Under this agreement, Samaritan has obtained exclusive rights
to sell Infasurf in Turkey, Serbia, Bosnia, Macedonia, Albania,
Egypt and Syria. The cumulative population of these countries
is greater than 180 million people.
Infasurf
is successfully marketed and sold in the United States by
Forest Laboratories, Inc. (NYSE:FRX - News) and is manufactured
by ONY Inc., a U.S. drug development company and a pioneer
in the field of Surfactant research. The decision to license
the exclusive rights to Infasurf
to Samaritan was based on the expertise of the Samaritan team
and their proven track record in regulatory affairs and in
the marketing and sales of specialty products in Eastern Europe.
Samaritan will register Infasurf with the health authorities
in the licensed countries.
Infasurf
is a specialist medication used to treat and prevent respiratory
distress syndrome (RDS), a lung condition that can occur in
prematurely born infants whose lungs have not completely developed.
RDS occurs when infants lack surfactant, a natural substance
normally produced in the body, which is necessary for lungs
to function normally.
Infasurf
is a bovine-derived, natural surfactant. Its unique advantages
include a high concentration of Surfactant Proteins -- and
in particular Surfactant Protein Type B (SP-B). SP-B is vital
for normal lung function (babies genetically lacking SP-B
die soon after birth). Infasurf
is approved by the U.S. FDA for the treatment or prevention
of Infant Respiratory Distress Syndrome.
In composition,
Infasurf
is the closest surfactant to natural surfactant. Infasurf
contains approximately 2% proteins (0.7% SP-B) as well as
DPPC, Cholesterol and other surface-active agents. Its benefits
are,
- Infasurf
is fast acting and excellent value for money.
- Infasurf
can be administered by either side port or catheter.
- Infasurf
is derived from cattle and thus contains no pork or pig
products and is thus not objectionable to Muslims.
- Infasurf
has been used in over 100,000 infants.
***
http://www.infasurf.net
***
Samaritan Pharmaceuticals:
``We LIV...to Save Lives.''
Samaritan is a
small-cap Biotech, driven to discover, develop and commercialize
innovative therapeutics for AIDS, Alzheimer's, Cancer and
Heart disease patients. Look at http://www.samaritanpharma.com.
Please register on Website so we can notify you of upcoming
conference calls, news and events.
***
The company disclaims
any information that is created by an outside party and endorses
only information that is communicated by its press releases,
filings and Website. This news release contains forward-looking
statements that reflect management's current beliefs about
the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development,
there are significant risks and uncertainties in the process
of development and regulatory review. There are no guarantees
that products will prove to be commercially successful. For
additional information about the factors that affect the company's
business, please read the company's latest Form 10-K/A filed
November 2, 2006. The company undertakes no duty to update
forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
